AXSMAxsome Therapeutics Inc
+3.8% today · +31.3% over a year
1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 33% of the instruments we score
Priced higher than most peers. No dividend.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 212)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Gross profit growth / assets (5 y)supports the score · better than 99% of peers
- Return on equityweighs on the score · better than 1% of peers
- Gross profit / assetssupports the score · better than 98% of peers
Red flags and notes
- Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Caution. Share count growing 3–10 % a year over three years. More in the glossary → Share count growing 3–10 % a year over three years.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 102.0
- P/S
- 10.9
- Free-cash-flow yield
- −0.8%
- Market cap (EUR)
- €75.8억
Profitability and debt
- Return on equity
- −245.1%
- Gross margin
- 93.2%
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- +3.8%
- 1 month
- −25.1%
- 1 year
- +31.3%
- Volatility, 1 yr
- 42.7%
- Max drawdown, 1 yr
- −38.7%
- Beta
- 0.90
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- Axsome Therapeutics, Inc.: 10-Q — Quarterly report for the period ending 2026-06-30
FactSEC EDGAR · Filing · 10 8월 2026
- Axsome Therapeutics, Inc.: 8-K — Results of operations; other events
FactSEC EDGAR · Filing · 10 8월 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | 1/10 | 1 · — | Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →Caution. Share count growing 3–10 % a year over three years. More in the glossary → | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
여기서 계약 해지 · EU 소비자: 구매 후 14일 이내 취소 가능.